Personal profile
Primary fields of research
Professor in Clinical cancer immune therapy and director of the translational research centre, Center for Cancer Immune Therapy (CCIT). CCIT is working translational and has a broad experience in preclinical as well as clinical research within cancer immunology and immunotherapy. Since 2005 CCIT has conducted numerous clinical trials including more than 200 cancer patients. It is an aim for CCIT to develop immunotherapeutic strategies for a broad spectrum of cancer diseases. Therefore, clinical trials have been carried out in diseases such as myeloma, melanoma, lung, -kidney, breast- and prostate cancer.
Current research
CCIT research includes e.g. more basic investigations on how the immune system reacts against cancer and which defect are involved in the sub-optimal function of the immune system leading to lack of cancer cell recognition and elimination.
Also, the research comprises clinical projects reaching from development and testing of peptide vaccines, dendritic cell based vaccines to T-cell therapy. The experimental treatments are frequently tested in combination with standard therapy such as chemotherapy with the intension of added efficacy.
Keywords
- Faculty of Health and Medical Sciences
- Immune therapy
- Melanoma
- T-cell therapy
- Cancer vaccines
- Dendritic cells
Collaborations and top research areas from the last five years
Research output
-
Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis
Garitaonaindia, Y., Khan, S., Friis, R., Kjær, S., Borch, T. H., Ruhlmann, C., Guldbrandt, L. M., Luczak, A. A., Schmidt, H., Bastholt, L., Svane, I. M., Donia, M. & Ellebaek, E., 2026, In: Journal of the National Cancer Institute. 118, 2, p. 261-268 8 p.Research output: Contribution to journal › Journal article › Research › peer-review
-
Immune Cell Modulation of Patient-Matched Organoid Drug Response in Precision Cancer Medicine Platform
Kjølle, S., Presti, M., Roque, J. D. P., Bisgaard, L. H., Beceiro Ramos, D., Zornhagen, K. W., Yde, C. W., Schmidt, A. Y., Verdys, P., Højgaard, M., Lassen, U., Svane, I. M., Rohrberg, K. S., Donia, M. & Erler, J. T., 29 Jan 2026, In: Cells. 15, 3Research output: Contribution to journal › Journal article › Research › peer-review
1 Citation (Scopus) -
Risk of Colitis in Patients With Inflammatory Bowel Disease or Microscopic Colitis Exposed to Checkpoint Inhibitors: A National Danish Cohort Study
Dahl, E. K., Christensen, K. R., Jacobsen, H. A., Kverneland, A., Dige, A., Svane, I. M., Donia, M., Bjerrum, J. T. & Seidelin, J. B., 2026, (E-pub ahead of print) In: JCO Oncology Practice.Research output: Contribution to journal › Journal article › Research › peer-review
-
18F-FDG PET/CT assessment of metabolic tumor burden predicts survival in patients with metastatic posterior uveal melanoma
Hindso, T. G., Martinussen, T., Bjerrum, C. W., Keller, S. H., Loft, A., Sjøl, M. B., Nissen, K., Faber, C., Donia, M., Svane, I. M., Ellebaek, E., Heegaard, S., Kiilgaard, J. F. & Madsen, K., 2025, In: Scientific Reports. 15, 1, 13 p., 4110.Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile4 Citations (Scopus)29 Downloads (Pure) -
A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE)
Chen, I. M., Theile, S., Madsen, K., Johansen, J. S., Lorentzen, T., Toxværd, A., Høgdall, E., Svane, I. M. & Nielsen, D., 2025, In: Immuno-Oncology and Technology. 26, 7 p., 101054.Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile2 Citations (Scopus)24 Downloads (Pure) -
Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment
Turcotte, S., Donia, M., Gastman, B., Besser, M., Brown, R., Coukos, G., Creelan, B., Mullinax, J., Sondak, V. K., Yang, J. C., Rohaan, M. W., Marie Svane, I., Lotze, M. T., Haanen, J. B. A. G. & Goff, S. L., 2025, In: Journal for ImmunoTherapy of Cancer. 13, 1, 16 p., e010207.Research output: Contribution to journal › Review › peer-review
Open AccessFile20 Citations (Scopus)2 Downloads (Pure) -
Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes
Borch, T. H., Andersen, R., Hendel, H. W., Madsen, K., Ellebaek, E. & Svane, I. M., 2025, In: Journal for ImmunoTherapy of Cancer. 13, 2, 5 p., e010575.Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile1 Citation (Scopus)1 Downloads (Pure) -
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020
Ascierto, P. A., Tang, H., Dolfi, S., Nyakas, M., Marie Svane, I., Muñoz-Couselo, E., Grob, J. J., Gomez-Roca, C. A., Chiarion-Sileni, V., Peltola, K., Larkin, J., Melero, I., Callahan, M., Dummer, R., Djidel, P., Warad, D., Reusser-Wolf, D., Lipson, E. J. & Garnett-Benson, C., 2025, In: Journal for ImmunoTherapy of Cancer. 13, 2, 14 p., e009773.Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile4 Citations (Scopus)1 Downloads (Pure)